Technical Analysis for ZNTL - Zentalis Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Outside Day | Range Expansion | 1.92% | |
| Wide Bands | Range Expansion | 1.92% | |
| NR7 | Range Contraction | 6.69% | |
| Narrow Range Bar | Range Contraction | 6.69% | |
| Wide Bands | Range Expansion | 6.69% | |
| Down 3 Days in a Row | Weakness | 6.69% | |
| Fell Below 20 DMA | Bearish | 4.59% | |
| Fell Below 50 DMA | Bearish | 4.59% | |
| MACD Bearish Signal Line Cross | Bearish | 4.59% | |
| New Downtrend | Bearish | 4.59% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | 33 minutes ago |
| Down 3% | about 4 hours ago |
| Down 2 % | about 4 hours ago |
| Down 1% | about 4 hours ago |
| Up 5% | 1 day ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/04/2024
Zentalis Pharmaceuticals LLC is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin Bunker on December 23, 2014 and is headquartered in New York, NY.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Drugs Breast Cancer Treatment Of Breast Cancer Epidermal Growth Factor Receptor Hormones Tyrosine Kinase Receptors Her2 Her2/Neu Molecule Therapeutics Transcription Factors Estrogen Antiestrogens Estrogen Receptor Receptor Positive Selective Estrogen Receptor Degraders Metastatic Breast Cancer
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Drugs Breast Cancer Treatment Of Breast Cancer Epidermal Growth Factor Receptor Hormones Tyrosine Kinase Receptors Her2 Her2/Neu Molecule Therapeutics Transcription Factors Estrogen Antiestrogens Estrogen Receptor Receptor Positive Selective Estrogen Receptor Degraders Metastatic Breast Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 18.07 |
| 52 Week Low | 2.66 |
| Average Volume | 2,367,846 |
| 200-Day Moving Average | 7.77 |
| 50-Day Moving Average | 3.42 |
| 20-Day Moving Average | 3.39 |
| 10-Day Moving Average | 3.60 |
| Average True Range | 0.36 |
| RSI (14) | 44.13 |
| ADX | 24.79 |
| +DI | 24.79 |
| -DI | 24.06 |
| Chandelier Exit (Long, 3 ATRs) | 3.36 |
| Chandelier Exit (Short, 3 ATRs) | 3.74 |
| Upper Bollinger Bands | 4.32 |
| Lower Bollinger Band | 2.45 |
| Percent B (%b) | 0.36 |
| BandWidth | 55.14 |
| MACD Line | 0.02 |
| MACD Signal Line | 0.08 |
| MACD Histogram | -0.0657 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.58 | ||||
| Resistance 3 (R3) | 3.55 | 3.38 | 3.51 | ||
| Resistance 2 (R2) | 3.38 | 3.26 | 3.39 | 3.48 | |
| Resistance 1 (R1) | 3.25 | 3.19 | 3.32 | 3.28 | 3.45 |
| Pivot Point | 3.08 | 3.08 | 3.11 | 3.09 | 3.08 |
| Support 1 (S1) | 2.95 | 2.96 | 3.02 | 2.98 | 2.81 |
| Support 2 (S2) | 2.78 | 2.89 | 2.79 | 2.78 | |
| Support 3 (S3) | 2.65 | 2.78 | 2.76 | ||
| Support 4 (S4) | 2.68 |
